Is Candida glabrata intrinsically resistant to fluconazole or to all azole antifungals, what mechanisms cause this resistance, and can voriconazole (generic: voriconazole) be used in a patient with chronic calcific pancreatitis, pancreatic diabetes, a prior Frey procedure, and right pyopneumothorax whose isolate is reported susceptible?

Candida glabrata Azole Resistance and Voriconazole Use

Candida glabrata is NOT intrinsically resistant to all azoles, but it has intrinsically reduced susceptibility to fluconazole specifically, and if your isolate is reported susceptible to voriconazole, you can use it—though echinocandins remain superior first-line agents for this patient with pyopneumothorax.

Understanding C. glabrata Azole Resistance Pattern

C. glabrata exhibits a dose-dependent susceptibility pattern to fluconazole rather than complete intrinsic resistance 1. The FDA label explicitly states that "many isolates are intermediately susceptible" 1. This is fundamentally different from C. krusei, which should be considered truly resistant to fluconazole 1.

Key Distinction:

• Fluconazole: C. glabrata has intrinsically reduced susceptibility (many isolates intermediate, MIC 16-32 mcg/mL)
• Other azoles (voriconazole, posaconazole): Variable susceptibility—NOT universally resistant
• C. krusei: Truly intrinsically resistant to fluconazole

Mechanisms of Azole Resistance in C. glabrata

The primary resistance mechanism involves upregulation of efflux pumps, not target enzyme alterations 1, 2, 3:

Dominant Mechanism:

• Efflux pump overexpression: Upregulation of CDR1 and CDR2 genes (ATP-binding cassette transporters) 2, 3, 4
• Driven by gain-of-function mutations in PDR1 transcription factor 2, 5, 6
• Results in coordinate upregulation of multiple drug transporters 2

Why NOT Target Enzyme Changes:

• ERG11 (lanosterol 14-α-demethylase) mutations are rare or absent in C. glabrata 3
• Unlike other Candida species, C. glabrata resistance is almost exclusively efflux-mediated 3, 4

The FDA label confirms: "Resistance in Candida glabrata usually includes upregulation of CDR genes resulting in resistance to multiple azoles" 1.

Cross-Resistance Between Azoles

Critical caveat: Cross-resistance between fluconazole and voriconazole is common but not universal 3, 7:

• Fluconazole-resistant isolates frequently show cross-resistance to voriconazole 3, 7
• However, voriconazole MICs are typically lower than fluconazole MICs 7, 8
• The FDA label for voriconazole notes that C. glabrata MIC₉₀ was 4 μg/mL in clinical studies, with 26% of isolates resistant 9

Can You Use Voriconazole in This Patient?

Yes, voriconazole can be used IF the isolate is confirmed susceptible by testing 10:

Guideline-Based Approach:

1. Susceptibility testing is mandatory: The IDSA strongly recommends azole susceptibility testing for all clinically relevant Candida isolates 10

2. If voriconazole-susceptible: Voriconazole 200-300 mg (3-4 mg/kg) twice daily can be used as step-down therapy after initial echinocandin 10

3. Dosing for C. glabrata: Use the higher end of dosing (300 mg or 4 mg/kg twice daily) given reduced susceptibility patterns 10

Clinical Context for Your Patient:

For a patient with pyopneumothorax (empyema thoracis):

• The 2025 ECMM guideline addresses Candida empyema thoracis 11
• Echinocandins remain preferred for serious infections like this
• Voriconazole is acceptable as step-down oral therapy once clinically stable 10

Treatment Algorithm:

Initial therapy (first 5-7 days):

• Start with echinocandin (anidulafungin 200 mg load, then 100 mg daily) 10
• This is especially important given the patient's complicated medical history and serious infection

Step-down therapy (if all criteria met):

• Patient is clinically stable
• Repeat cultures negative
• Isolate confirmed voriconazole-susceptible
• Then transition to voriconazole 400 mg twice daily × 2 doses, then 300 mg twice daily 10

Important Pitfalls to Avoid

1. Don't assume susceptibility: Even if voriconazole is reported susceptible, preclinical data suggest that achieving adequate PK/PD targets may require trough levels of 1-4 mg/L for isolates with MICs 0.25-1 mg/L 8

2. Monitor therapeutic drug levels: Consider voriconazole therapeutic drug monitoring, targeting troughs >1-2 mg/L for C. glabrata

3. Don't use fluconazole: Even at high doses (800 mg daily), fluconazole is inferior to echinocandins for C. glabrata and should only be considered if the isolate is explicitly fluconazole-susceptible 10

4. Source control: Address the pyopneumothorax with drainage procedures as needed—antifungals alone are insufficient 11

5. Echinocandin resistance: Given prior healthcare exposure, consider testing for echinocandin susceptibility (FKS mutations) 10, 4

The bottom line: Start with an echinocandin, then transition to voriconazole only after confirming susceptibility and clinical stability 10.